Social Media Ideas for Bispecific T-Cell Engager

AbbVie’s bispecific T-cell engager shows promise in ph. 3 multiple myeloma trial

AbbVie released positive phase 3 data Thursday showing that its bispecific T-cell engager etentamig improved response rates and progression-free survival in patients with relapsed/...

Taking a BiTE Out of Cancer at Intermountain Health

Bispecific T-cell Engager (BiTE) therapy through the Intermountain Health Oncology Clinical Program is Bringing Care Close to Home The post Taking a BiTE Out of Cancer at Intermoun...

AbCellera, Vertex partner on next-gen T-cell engagers

The deal adds to a growing streak of partnerships involving new types of T cell engagers and gives Vertex another chance to broaden a business still reliant on cystic fibrosis medi...

Engineered bispecific antibodies boost macrophage killing of B-cell lymphoma

A new study describes a high-throughput strategy for engineering bispecific antibodies that could help macrophages destroy malignant B cells more efficiently, offering a potential...

Bispecific CAR T Cells Eliminate AChR-Specific B Cells in Myasthenia Gravis Models

A Precision-Built T-Cell Therapy Targets the B Cells Behind Myasthenia Gravis Myasthenia gravis is an autoimmune disorder in which the immune system attacks the body’s own machiner...

Context scraps bispecific T-cell engager program to extend cash runway deeper into 2027

Context Therapeutics has stopped development of the bispecific T-cell engager CT-95, freeing up cash to extend its runway beyond readouts on its two priority clinical programs.

Vertex’s latest autoimmune TCE play involves $28M upfront to AbCellera

AbCellera’s T-cell engager platform has reeled in a second client this summer, with Vertex paying $28 million upfront for a collaboration that will include autoimmune conditions.

CAR-T Made easy

Chimeric antigen receptor (CAR) therapy is away you harness the specificity potential of antibodies and the killing potential of T cells. You make T cells to express bits of an ant...

In silico clinical trials of BiTE expression by oncolytic viruses reveal the impact of patient heterogeneity on dosage p...

by Adrianne L. Jenner, Robyn P. Araujo, Noa L. Levi, Guy Ungerechts, Christine E. Engeland, Johannes P. W. Heidbuechel Immunotherapies have become a transformative therapeutic str...

Bicistornic Vectors + piggyBac = Improved Antibody Cell Line Production

To produce stable cell lines for monoclonal antibody production, manufacturers typically use the piggyBac transposon system. For larger, multi-specific antibodies that have payload...

Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone

Filing supports potential development of radiopharmaceuticals, T-cell engagers and other immune-based approaches using a versatile platform approach

Tolerance Bio jumps into phase 2 with $260M deal for thymus-targeting fusion protein

Tolerance Bio has vaulted into the clinic by agreeing to pay NeoImmuneTech up to $260 million for rights to a fusion protein in certain thymus-related indications in the Americas a...

Engitix Licenses Lonza’s Technology to Advance ADC Therapies

Lonza, through one of its affiliated companies, is eligible to receive upfront, clinical, regulatory, and commercial milestone payments, plus royalties on the net sales of resultin...

Bristol Myers’ pivotal CAR-T multiple myeloma trial hits primary endpoint

A pivotal trial of Bristol Myers Squibb’s GPRC5D-directed CAR-T cell therapy has hit its primary endpoint, furthering the drugmaker’s efforts to challenge Johnson & Johnson for...

Cellogen Therapeutics is developing CAR-T cell therapies for blood cancers in India

The Delhi company designs and manufactures its own cell and gene therapies and is preparing a first clinical trial with Christian Medical College, Vellore.

Singapore’s Tikva targets solid cancer barrier with US$8M Series A

For years, cell therapy has carried one of oncology’s most striking contradictions. It has changed the outlook for some blood cancer patients, yet has struggled to make the same im...

Immuneel, Tata Memorial Centre partner to advance cell and gene therapy research

Among the first projects identified under the partnership is a Phase 2 extension study evaluating the safety and efficacy of IMN-003A cell therapy in adult and paediatric patients...

Genentech doubles down on ADC-resistant cancers with $1B DualityBio pact

Roche’s Genentech is paying DualityBio $45 million upfront for rights to antibody-drug conjugates (ADCs) designed for the growing pool of patients who progress after treatment with...

TScan axes 75% of workforce to make room for solid tumor programs

TCR-T specialist TScan Therapeutics will reduce its workforce by 75% following the pause of its hematological and autoimmune programs.

How to Teach T Cells to Track Cancer Like a Hound Dog

The immune system is full of T cells that could hunt down and destroy tumors, if they were primed. Now, a UC San Francisco team has invented a way to do this by combining immune ce...

Notch Signaling Switch Enables Scalable Helper T Cell Production for CAR T

By modulating Notch and T cell receptor signaling, scientists have produced functional CD4+ T cells from iPSCs, potentially advancing scalable, off-the-shelf CAR T therapies. The p...

<![CDATA[Steer Bio Targets Lymphedema with Regenerative Cell Therapy Platform]]>

Bispecific Antibody Purification’s Complexity Problem and How to Fix It

Bispecific antibodies are gaining momentum, and the demands on downstream purification will continue to grow. The case studies presented here illustrate how analytical insight form...

Modular Antibody–ADC Click Chemistry Overcomes Tumor Drug Resistance in Mice

The team’s strategy—called antibody–ADC click—relies on the rapid ligation between trans‑cyclooctene (TCO) and tetrazine moieties. The post Modular Antibody–ADC Click Chemistry Ove...